恋火绒雾持妆粉底液
Search documents
丸美生物(603983):Q3净利润恢复增长,大单品表现持续亮眼
HUAXI Securities· 2025-10-31 13:12
Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of 2.45 billion yuan for Q1-Q3 2025, representing a year-on-year increase of 25.51%, with a net profit of 244 million yuan, up 2.13% year-on-year [2] - The company continues to optimize its product structure, with strong performance from key products, particularly in the eye care and skincare categories [3] - The gross profit margin for Q1-Q3 2025 was 74.91%, showing a slight increase, while the net profit margin was 9.95%, reflecting a decrease [4] Revenue Summary - For Q3 2025, the company achieved a revenue of 686 million yuan, a year-on-year increase of 14.28% [2] - Breakdown of revenue by product category for Q3 2025: - Eye care: 149 million yuan (+20.10%) - Skincare: 306 million yuan (+42.05%) - Cleansing: 67 million yuan (+23.06%) - Beauty: 148 million yuan (-26.71%) - Other: 16 million yuan (+285.46%) [3] Profitability Summary - The company’s gross profit margin for Q3 2025 was 75.72%, an increase of 1.20 percentage points year-on-year [4] - The net profit margin for Q3 2025 was 10.13%, a slight decrease of 0.24 percentage points year-on-year [4] - The company plans to enhance cost control and stabilize expenses to improve profitability [5] Expense Summary - The operating expense ratio for Q1-Q3 2025 was 63.77%, an increase of 3.12 percentage points year-on-year [5] - For Q3 2025, the operating expense ratio rose to 69.04%, with increases in sales and management expenses attributed to heightened competition and increased team size [5] Investment Recommendations - The company is expected to achieve synchronized growth in revenue and profit due to brand strengthening and operational efficiency improvements [6] - Revised revenue forecasts for 2025-2027 are 3.68 billion, 4.48 billion, and 5.42 billion yuan respectively, with net profits of 397 million, 493 million, and 631 million yuan [6] - The estimated EPS for 2025-2027 is projected to be 0.99, 1.23, and 1.57 yuan, with corresponding PE ratios of 35, 28, and 22 times [6]